|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Sales, net | |||||
| Cost of sales | |||||
| Product | |||||
| Royalty fees | |||||
| Total cost of sales | |||||
| Gross profit (loss) | |||||
| Operating expenses: | |||||
| Sales and marketing | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment of assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income - TIA | |||||
| Unrealized gain (loss) on debt and equity securities | |||||
| Gain on trading debt and equity securities | |||||
| Litigation proceeds | |||||
| Interest and other income | |||||
| Interest expense | |||||
| Net loss before income taxes | |||||
| Provision (benefit) for income taxes | |||||
| Net loss | |||||
| Preferred Stock dividend requirements | |||||
| Net loss applicable to common shareholders | |||||
| Basic loss per share | |||||
| Diluted loss per share | |||||
| Weighted average common shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...